#Lomitapide

[pharmaceutical0]

Lomitapide M1 - CAS. No. 182439-41-4 - Simson Pharma

Simson Pharma is the leading manufacturer and exporters of Lomitapide M1 — CAS. №182439–41–4. Buy Lomitapide M1 from Simson Pharma at best competitive price

CAT. No. L1020002

CAS. No. 182439–41–4

Mol. F. C19H19F3N2O

Mol. Wt. 348.36 g/mol

Every compound produced by Simson Pharma is accompanied by Certificate of Analysis.

Read More:- https://www.simsonpharma.com/product/lomitapide-m1

[streetdrugsexpress]

Buy Juxtapid Lomitapide 5mg Capsules - Street Drugs Express

Buy Juxtapid Lomitapide 5mg Capsules from streetdrugsexpress.com. Juxtapid capsules contain lomitapide mesylate, a synthetic lipid-lowering agent for oral administration. Available in price:$18,000.00

Visit: https://streetdrugsexpress.com/product/juxtapid-lomitapide-capsules-5mg-28-capsules/

[pushingarrows]

Lomitapide - an inhibitor of the microsomal triglyceride transfer protein (MTTP) as a lipid lowering agent to reduce LDL cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). It can be used in combination with other cholesterol lowering medications. MTTP is necessary for very low-density lipoprotein (VLDL) assembly and secretion in the liver.

[streetdrugsexpress]

Buy Juxtapid Lomitapide 20mg Capsules - Street Drugs Express

Buy Juxtapid Lomitapide 20mg Capsules  from streetdrugsexpress.com. Juxtapid Lomitapide is a drug used as a lipid-lowering agent for the treatment of familial hypercholesterolemia. JUXTAPID capsules contain lomitapide mesylate, a synthetic lipid-lowering agent for oral administration.

Available in price:$18,000.00

Visit:https://streetdrugsexpress.com/product/juxtapid-lomitapide-capsules-20mg-28-capsules/

[pharmaphorumuk]

Regeneron preps for 2020 filing for new cholesterol drug after trial success

Regeneron has announced data that could create a niche for its latest cholesterol drug evinacumab in a small group of patients who do not respond to the strongest available medicines.

The US pharma is developing evinacumab to treat patients with homozygous familial hypercholesterolaemia (HoFH), with high levels of “bad” low-density lipoprotein (LDL) cholesterol despite treatment with other lipid-lowering therapies including maximum statin doses, and PCSK9 inhibitors.

HoFH affects only 1,300 people in the US, but those affected often experience early atherosclerotic disease and sometimes suffer cardiac events as early as their teenage years.

Despite this tiny patient population there is already talk of peak US sales in the region of $200 million to $400 million.

The latest trial was asking whether evinacumab can cut cholesterol levels after PCSK9 drugs such as Sanofi/Regeneron’s Praluent (alirocumab) and Amgen’s Repatha (evolocumab) have failed.

Patients had also been treated with therapies including ezetimibe, LDL apheresis, and lomitapide.

According to the phase 3 ELIPSE HoFH trial, the answer to this question is “yes” – adding evinacumab to other lipid-lowering therapies decreased LDL cholesterol by 49% on average, compared with lipid lowering therapies alone.

Patients entered the trial with LDL cholesterol levels of 255 mg/dL despite treatment with available therapies.

There was a 132 mg/dL absolute change in LDL cholesterol from baseline compared with placebo and 47% achieved cholesterol levels less than 100 mh/dL compared with 23% for placebo.

Similar levels of LDL cholesterol-lowering were also observed in the most difficult-to-treat patients who often don’t respond to certain other therapies, described as “null/null” or “negative/negative” patients.

Evinacumab also reduced apolipoprotein B (ApoB), non-HDL cholesterol and total cholesterol compared to placebo.

In 2017 the FDA granted the drug Breakthrough Therapy designation for hypercholesterolaemia in patients with HoFH.

This paves the way for a potential fast review when Regeneron files data from this and other evinacumab trials with the regulator next year.

  The post Regeneron preps for 2020 filing for new cholesterol drug after trial success appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/news/evinacumab-regeneron-cholesterol-drug-trial/

[yuking2020]

cas:202914-84-9

采购(1) 供应(6)

采购 Lomitapide Mesylate 甲磺酸洛美他派 202914-84-9 实单求购5g，有货的联系！

[azveille]

Hypercholestérolémie familiale homozygote : le taux de LDL-cholestérol divisé par deux par l'évinacumab

Le nouvel anticorps monoclonal hypolipémiant évinacumab a divisé par deux le taux de LDL-cholestérol chez des patients souffrant d'hypercholestérolémie familiale homozygote, dans une étude randomisée, annonce le laboratoire Regeneron mercredi.

Cet anticorps est un anti-ANGPTL3 (angiopoietin-like 3). L'ANGPTL3 agit comme inhibiteur de la lipoprotéine lipase et de l'endothelial lipase, qui jouent un rôle central dans le métabolisme des lipides. Des mutations rares apparaissant naturellement dans le gène de l'ANGPTL3 sont associées à des taux de triglycérides et de cholestérol faibles; c'est la raison pour laquelle un anti-ANGPTL3 a été développé.

Dans l'étude ELIPSE HoFH, 65 patients présentant une hypercholestérolémie familiale homozygote, dont le taux de LDL-C restait élevé à 2,55 g/l malgré des traitements hypocholestérolémiants par statine à dose maximale tolérée, anti-PCSK9, ézétimibe, aphérèse de LDL ou lomitapide, ont été randomisés dans une proportion 2:1 entre l'ajout à ces traitements de l'évinacumab ou d'un placebo, toutes les 4 semaines en sous-cutané.

Après 24 semaines, par rapport au placebo, l'évinacumab a diminué de 49% le taux de LDL-cholestérol.

Cela correspondait à une baisse de 1,32 g/l en moyenne. La baisse du LDL-C a été observée dès deux semaines après le début du traitement et a perduré jusqu'à 24 semaines.

Près de la moitié des patients (47%) ont vu leur taux de LDL-C passer en-dessous de 1 g/l avec l'anti-ANGPTL3 alors que ce fut le cas de 23% dans le groupe placebo.

Regeneron indique dans son communiqué que des baisses de la cholestérolémie similaires à celles des autres patients ont été observées chez les patients dits "null/null" ou "negative/negative", les plus difficiles à traiter et qui généralement ne répondent pas aux autres traitements.

L'évinacumab a été généralement bien toléré, indique la firme. Il y avait globalement moins d'effets indésirables dans le groupe évinacumab que dans le groupe placebo. Les deux effets indésirables plus fréquents avec l'anticorps étaient des syndromes grippaux (11%) et des rhinorrhées (7%). Il n'y avait pas de différence de risque de diarrhée, douleur abdominale ou nausée. Durant l'étude on n'a déploré aucun décès ni événement cardiovasculaire majeur, ni aucun trouble hépatique.

[marketresearchinsight-blog]

Hyperlipidemia Drugs Market Share, Competitive Insights, Region, Segments And Forecast By 2022

San Francisco, 28 September 2018 - The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, according to a new report by Grand View Research, Inc., expanding at a CAGR of 2.3% during the forecast period. Several factors, such as increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia, are stoking the growth of the market.

Hyperlipidemia is the most common type of dyslipidemia and is generally caused by abnormally high lipid levels in the blood. This condition can occur due to genetic factors (primary hyperlipidemia) as well as other factors such as poor diet and unhealthy lifestyle (secondary hyperlipidemia). Statins are the first line of treatment for secondary hyperlipidemia.

Target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users. The revenue share of statin users has been declining. The nonstatin users segment consists of statin intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population. Nonstatin users are seeking high-efficacy alternatives and this is anticipated to boost the revenue of this segment.

Upcoming patent expirations are expected to lead to greater genericization in the market, mostly among statins, cholesterol absorption inhibitors, and combination drugs. However, new product launches are anticipated to continue to drive the market. Several novel mechanisms of action such as ACL inhibition, DGAT2 inhibition, and anti-ANGPTL-3 are being investigated for their potential for treatment of hyperlipidemia as well as for reducing the risk of CVD.

To request a sample copy or view summary of this report, click the link below: www.grandviewresearch.com/industry-analysis/hyperlipidemia-drugs-market

Further key findings from the report suggest:

Statins dominated the drug classes in 2016 owing to their high usage as the first line of therapy

Recent launch of PCSK9 inhibitors, such as Repatha and Praluent, is likely to change the current therapeutic scenario due to their improved efficacy and safety profile

PCSK9 inhibitors are expected to displace existing expensive therapies, lomitapide, and mipomersen for the treatment of homozygous FH patients

Europe was the leading regional market in 2016. It is estimated to maintain its dominance till 2022 owing to high prevalence of hypercholesterolemia

There are fewer growth opportunities in Japan due to unavailability of key pipeline drugs such as bempedoic acid

AstraZeneca; Merck & Co., Inc.; Pfizer, Inc.; DAIICHI SANKYO COMPANY, LIMITED; Amgen, Inc.; and Sanofi are some of the key players operating in this market

Amgen, Inc.; Sanofi; and Esperion are expected to have the highest shares in this market by 2022

Browse More Reports Of Same Category: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global hyperlipidemia drugs market based on drug class and region:

Hyperlipidemia Drug Class Outlook (Revenue, USD Million, 2016–2022)

Statins

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

Fibric Acid Derivatives

PCSK9 Inhibitors

Combination

Miscellaneous

Hyperlipidemia Regional Outlook (Revenue, USD Million, 2016–2022)

US.

UK.

Germany

Spain

France

Italy

Japan

Browse Press Release of this Report: www.grandviewresearch.com/press-release/global-hyperlipidemia-drugs-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com